The angiogenic process and cancer

Omar López1, Yack Magariño2, René Delgado3

1Centro de Estudio para las Investigaciones y Evaluaciones Biológicas, IFAL, UH Ave. 23 #21425 entre 214 y 222, La Coronela, La Lisa, Ciudad de La Habana, Cuba
2Centro de Química Biomolecular, CQB Calle 200, Esq. 21, Playa, Ciudad de La Habana, Cuba
3Centro Nacional Coordinador de Ensayos Clínicos, CENEC Calle 200, Esq. 21, Atabey, Playa, Ciudad de La Habana, Cuba
E-mail: omarlopez@infomed.sld.cu

ABSTRACT

Angiogenesis, the growth of new capillaries from pre-existing vessels, is closely related to essential physiological processes for example: embryogenesis, reproductive cycle, and wound healing. It is also associated with pathological conditions such as: tumor progression, metastasis, diabetic retinopathy, hemangioma, arthritis, psoriasis and atherosclerosis, among other chronic diseases. The development of specific anti-angiogenic agents arises as an attractive therapeutic approach to treat cancer and other angiogenesis-dependent diseases. Many of these agents are being evaluated in clinical trials and have shown promising antitumor activity. This review attempts to provide a comprehensive overview of key knowledge accumulated on angiogenesis, as well as its role in cancer, including the components of signal transduction pathways that have been explored in this process. Additionally, this review focuses on the current approaches for the discovery of new compounds that inhibit angiogenesis, emphasizing on the clinical developmental status of antiangiogenic drugs.

Keywords: Angiogenesis, cancer, tumor

El proceso angiogénico y el cáncer. La angiogénesis, el crecimiento de nuevos capilares a partir de los vasos pre-existentes, se encuentra estrechamente relacionado con procesos esenciales para el organismo, que son puramente fisiológicos; por ejemplo la embriogénesis, el ciclo reproductivo y la cicatrización de heridas. También se encuentra asociado a condiciones patológicas como el desarrollo de tumores, metástasis, retinopatía diabética, hemangioma, artritis, psoriasis y aterosclerosis, entre otras enfermedades crónicas. El desarrollo de compuestos anti-angiogénicos específicos se plantea como un atractivo enfoque terapéutico para el tratamiento del cáncer y otras enfermedades dependientes de la angiogénesis. Muchos de estos agentes están siendo evaluados en ensayos clínicos y han mostrado actividad antitumoral prometedora. Esta revisión pretende dar una visión general de los principales conocimientos acumulados acerca de la angiogénesis y su papel en el cáncer, incluyendo también los componentes de las vías de transducción de señales que se han investigado de este proceso. Además esta revisión se centra en los enfoques actuales para el descubrimiento de nuevos compuestos que inhiben la angiogénesis, con énfasis en el estado de desarrollo clínico del producto anti-angiogénico.

Palabras clave: Angiogénesis, cáncer, tumor

Introduction

The establishment and maintenance of a vascular network is an essential requirement in growth of healthy and neoplastic tissues. The cardiovascular system is the first organ system to be developed and start functioning during embryogenesis [1]. Formation of new blood vessels involves two processes: vasculogenesis and angiogenesis; so it is very important to comprehend their respective conceptual differences. Vasculogenesis is the primary in situ differentiation of endothelial cells (EC) from their mesodermic precursors and its subsequent structuring in a primary capillary plexus [2]. This is a highly regulated process under physiological conditions which is activated during a short period of time until inhibition, for example embryogenesis [3]. On the other hand, angiogenesis is defined as the formation of new blood vessels from the pre-existent vascular layer. This event occurs during the embryonary development, also in postnatal life of the organism [4].

Angiogenesis has to be inhibited or absent in adult tissues under normal conditions. It only takes place during wound healing and in the female reproductive cycle [5]. These processes are associated to the so-called: physiological angiogenesis and are produced under strict functional control mechanisms to achieve a proper balance between the positive and negative regulators (stimulators and inhibitors of angiogenesis, respectively) [6].

However, many diseases are related to the pathological angiogenesis. It has been described as one of the particular properties of cancer, playing a key role for tumor development, invasion and metastases. This only occurs in response to a stimuli or damage, breaking the balance between the regulators; and leading to an overproduction of stimulators and/or a suppression of angiogenic inhibitors [6]. When the resting EC become activated by a pro-angiogenic signal, they release degradative enzymes that allow their migration, proliferation and final differentiation to form new blood vessels. Almost every field of medicine has to deal, in some way or another, with angiogenesis, associated to physiopathological processes. All the organ systems

Corresponding author

without exception are related to many diseases having angiogenesis as an essential component [5]. The present work is a review about angiogenesis as a process involved in oncological pathologies, also a comment on the development and use of angiogenesis inhibitors to fight cancer.

**Background**

Two important moments occurred in almost two centuries on the currently approved concept of angiogenesis as a key process for cancer development. The first one in 1887, when the British surgeon John Hunter described the process of angiogenesis as a formation of new blood vessels, which was continued during the XIX century by studying the details of the vascular anatomy of tumors. The second occurred between 1960’s and 1970’s decades, while beginning the research about angiogenesis related to tumor growth, that is, when Dr. Judah Folkman stated in 1971, the imaginative hypothesis that tumors depend on the angiogenic processes in growth [7]. However, it was not until 1990 that angiogenesis became central for studying cancer [6], with massive uprising of antiangiogenic products that are being evaluated in clinical trials. Research is being currently focused on obtaining compounds to modify the biology of the vascular endothelium to prevent tumor growth. These include: inhibiting endothelial proliferation, directly or by blocking the receptors of the growth factors associated to the vascular endothelium, negative regulation of the expression of these growth factors [8]; and prevention of EC migration by inhibiting the activity of matrix metalloproteinases (MMP).

**Characterizing the angiogenic process**

Angiogenesis is a stimuli-induced process with hypoxia as a main player [9], but it could be also induced by metabolic stimuli, as hypoglycemia and acidosis [10]. It is known that events such as: local vasodilation, increased vascular permeability and accumulation of extravascular fibrin occur in response to an angiogenic stimulus [11].

The process of tumor angiogenesis is a well-structured process, following a series of events, as depicted in figure 1, which are enumerated as follows:

1. Injured or ill tissues produce proteins named growth factors, which diffuse through the tissues towards the neighboring blood vessels.
2. These factors bind their specific receptors in the surface of EC on those blood vessels.
3. After this binding, the EC become activated. Signals are transduced from the cell surface into the nucleus, and the synthesis machinery of the EC begins to produce new molecules, including enzymes as the MMP.
4. The enzymes dissolve the surrounding basal membrane of the vessel, opening wholes on it.
5. The EC begin to divide (proliferate), migrating out of the vessel through the wholes in the basal membrane following the stimuli gradient.
6. At this point of the process, specialized molecules called adhesion molecules help to organize this migration by allowing the interaction between cells, also between these cells and the matrix.

7. The MMP are produced to dissolve the extracellular matrix in the leading edge of the growing blood vessel. The surrounding matrix also remodels as the vessel enlarges.
8. The EC are elongated and begin to adopt the tubular form of a blood vessel.
9. The nearest new blood vessels became connected to form a link allowing blood circulation.
10. Finally, the newly formed tubular blood vessel stabilizes by appearing smooth muscular cells and pericytes that bring structural support. Then, blood starts to flow [12].

This cascade of events is divided into an activation phase and a resolution phase. The first one comprises the initiation and progression by degradation of the basal membrane, cellular migration invasion to the extracellular matrix, EC proliferation and formation of capillary lumen. Resolution comprises termination and maturation of blood vessels, EC proliferation, the end of cellular migration, the basal membrane becoming reconstituted and maturing the complex endothelial junctions [11].

**Relationship among the different angiogenic mediators**

Angiogenesis, as any other biological process, involves many cellular components and aspects. Taking care of all the previous considerations, it depends on the control of EC functions, such as proliferation, migration and interactions with the extracellular matrix [13].

The EC usually exist in an inactive state into the vasculature, regulating the flux of nutrients of different biologically active molecules and also blood cell function. This role, as maintenance barrier of the endothelium, is exerted through receptors anchored in the endothelial membrane for many molecules, such as: growth factors, metabolites like nitric oxide and serotonin, and through specific junction molecules or other governing the interaction between these cells and the matrix [14].

EC activation can be positively or negatively regulated by several molecules, including the growth factors themselves and cytokine-related peptides, which are synthesized in normal or malignant cells [11]. Moreover, they include the best positive angio-

genesis regulators known so far as the vascular endothelium growth factor (VEGF) [15], and the basic fibroblast growth factor (bFGF) [16]. The effect of these factors oppose other cytokines’ ones, such as: the transforming growth factor beta (TGF-β) [17] and the tumor necrosis factor alpha (TNF-α) [18]. Both are polypeptides acting as pro-angiogenic factors in vivo; however, they do not favor endothelial growth in vitro. This has supported the hypothesis of these cytokines promoting angiogenesis indirectly, by inducing the production of positive regulators by stromal and chemo-attracted inflammatory cells [19], and tumor cells. Other cytokines have been described as angiogenic regulators in vivo, such as: interleukin-1 (IL-1) [20], the hepatocyte growth factor (HGF) [21], the epidermal growth factor (EGF) [22] and the platelet-derived growth factor (PDGF) [23], among others. Many of the interactions of EC with the extracellular matrix are favored by extracellular proteolytic events that depend on a set of proteases and their inhibitors, produced by activated EC and other cell types (tumor cells, macrophages, etc.) [24, 25]. Among them, MMP play a key role for migration of normal or tumor cells throughout the organism [26]. The MMP comprise a family of at least of 16 Zn2+-dependent endopeptidases that function extracellularly and are constitutively expressed [12, 25].

These are soluble enzymes that are secreted to the extracellular space, except the membrane-associated MMP [27] which bear a transmembrane domain in the carboxyl end and are subsequently localized on the cellular surface [28]. The MMP act as zymogens (the regulatory domain should be dissociated away from the catalytic domain for the enzyme to be activated). This dissociation is autocatalytic or due to the action of several enzymes such as: furin, plasmin or any other membrane-associated MMP, occurring on the surface of many cell types [29].

Proteolytic degradation of the extracellular matrix requires a strict regulation. It starts at transcriptional level by specific activated transcriptional complexes bind to regulatory elements in the genes coding for those proteolytic enzymes; also regulated by the balance of zymogens and their catalytically active counterparts; and by the binding of the activated enzymes and the zymogens to the tissular inhibitors of metalloproteinases (TIMP) [30, 31].

Once activated, the MMP can be inactivated by the above mentioned inhibitors and by the binding of plasmatic proteins as microglobulin-α2. The total balance of expression and activation of MMP is favored against the levels of TIMP and inhibition [29].

The cellular invasion, proliferation and migration processes not only depend on the enzymatic system, growth factors and their receptors, but also on the adhesion molecules involved [32]. They are classified in four families according to their structure and biochemical properties: integrins, the immunoglobulin superfamily, cadherins and selectins [33, 34].

For example, during invasion and migration, integrins mediate the interaction between EC and the extra- cellular matrix. Similarly, during the final stage of the angiogenic process (i.e., the formation of capillary links) they play an essential role in cell-to-cell and cell-matrix interactions [35].

**Angiogenesis-associated pathologies**

Some pathologies (such as ischemic tissue damage [36] or cardiac deficiency [37]) are associated to a low angiogenic activity, but generally neovascularization processes are associated to pathologies involving high angiogenic activity, such as: chronic inflammatory processes, rheumatoid arthritis [38], Crohn’s syndrome (inflammatory bowel disease) [39], diabetic retinopathy [40], hemangioma [41], psoriasis [42, 43], endometriosis (proliferation of endometrial tissue outside of the uterus) [44], and mainly cancer (either solid or hematological tumors) [45]. More recently, angiogenesis has also been involved in other disorders of varied origin such as: arteriosclerosis [46], obesity, asthma, infectious diseases, neurodegeneration and hypertension [47].

**Angiogenesis and cancer**

Tumors begin to grow as small aggregates of neoplastic cells outgrowing the basal layer, without any significant input of blood. Therefore, these aggregates are avascular [48]. This pre-vascular form of the tumor is denominated in situ carcinoma and is highly dependent on the proximal blood vessels for dioxygen and nutrients supply. The size of the carcinoma remains steady, without significant increase over time and limited by the balance of cellular proliferation and apoptosis/cell death [49]. Without vasculature, the tumor cannot grow beyond 1-2 mm long, because it only takes the oxygen and nutrients by diffusion. The oxygen only diffuses up to 100 mm between the capillary and the cell, only covering 3 to 5 lines of cells around the capillary [48].

Once the tumor is connected to circulation by new blood vessels, it can grow and tumor cells disseminated throughout the body, metastasizing [50]. This demonstration generated the novel concept that cancer can be therapeutically treated by antagonizing the angiogenic process. The timing recommended for the antiangiogenic treatment is that sufficient to guarantee the affluence of blood vessels to the tumor for adequate chemotherapy, but avoiding an abundant blood supply promoting metastasis, as represented in figure 2.

The process of tumor neovascularization comprises the release of pro-angiogenic factors (e.g., VEGF) by tumor cells, the growth of blood vessels and further expansion of the tumor.

The main triggering cause of angiogenesis toward the tumor is the hypoxic damage due to the increased distance between tumor cells and capillaries. Hypoxia induces the expression of VEGF and its receptor through the hypoxia inducible factor 1α (HIF-1α) [51], which is also a factor attracting macrophages [52-54]. Over time, some carcinoma cells can gain the capacity to express certain genes coding for natural angiogenic grow factors. On the other hand, some pro-inflammatory cells (mainly lymphocytes and macrophages) [55] are attracted by the tumor, also secreting growth factors. On the other hand, some pro-inflammation factors coding for natural angiogenic grow factors [56].

The capacity of tumors to induce and sustain the angiogenic process is attributed to two main changes. The first is a process of loss of function, by decreasing or negatively regulating of endogenous inhibitory proteins such as trombospondin-1 (TSP-1) [57] and IFN-α [58]. The second is a gain-of-function event,
by inducing pro-angiogenic growth factors. Among these growth factors, VEGF has been the main target of tumor angiogenesis suppression studies, due to its overexpression as part of a change in most of the tumors towards an angiogenic phenotype [59-62].

The newly synthesized blood vessels are not exactly similar to that pre-existent in healthy tissues. Tumor blood vessels show a disproportionately increased inner diameter in respect to the thick of the vascular wall, and a lower number of smooth muscle cells and pericytes. This implies a notable thickness and fragility of the vascular wall, favoring the development of aneurism-like dilations, irregular blood flow, and zones without blood irrigation and increased vascular permeability [63].

Besides, tumor blood vessels express specific markers as endoglin (CD-105/EDG), which are dimeric components of the cell surface acting as TGF-β receptors. This complex is abundantly expressed in the tumor endothelium but not in the normal blood vessels [44].

The EC of the immature blood vessels require signals to survive, or are eliminated by program cell death or apoptosis. The VEGF inhibits apoptosis of these EC in the immature tumor blood vessels by inducing the expression of the antiapoptotic Bcl2, A1 XIAP and surviving proteins [64].

Tumors with high levels of VEGF produce an excessively permeable vasculature susceptible to leakage, increasing the interstitial pressure inside the tumor. The morphology of tumor blood vessels also impairs blood flow, oxygen and nutrient supply. All these influence the conventional antitumoral therapy, due to a misbalanced distribution of the chemotherapeutic agents inside the tumor with some of its regions unreachable by these agents, therefore, help neoplastic cells to survive. Additionally, oxygen levels are not homogeneous inside the tumor, with relatively hypoxic zones being insensitive to radiotherapy [65, 66]. Consequently, the use of anti-VEGF agents could be ideal to aid chemotherapy and radiotherapy, hampering tumor growth while improving treatment for tumor destruction [67-69].

Frequently, when a primary tumor is destroyed, secondary tumors will arise if metastasis developed. In this sense, the main source of the Angiostatin (a natural endogenous antiangiogenic) is eliminated with primary tumor removal, favoring the development of secondary tumors [63]. Angiostatin is commonly produced by solid tumors or cells at their environment without affecting primary tumor growth. By this mechanism, the primary tumor develops while endogenously controlling the development of distant tumors [44].

Tumors produce more angiogenesis promoting than inhibitory factors. This could be explained by the increased half life of inhibitory factors in the blood stream (for example, angiostatin circulates up to 5 days, while pro-angiogenic factors last less than 5 days). Thus, pro-angiogenic factors mainly act in the vicinity of the tumor, while inhibitors easily act on distant tumors [50].

Most of the neoplastic cells show increased genetic instability, with frequent mutations arising and causing cellular changes that generate resistance to cytotoxicity of conventional antineoplastic drugs [70]. When referring to tumor genetics, several oncogenes have to be mentioned, such as V-ras, K-ras, V-raf, fos and the E6 protein of the human papillomavirus 16, all of them promoting angiogenesis by producing growth factors, cytokines and proteolytic enzymes [71, 72]. On the contrary, there are tumor suppressor genes, such as Rh, c-jun and p53, the last causing HIP-1 degradation, inhibiting VEGF production and stimulating the TSP-1 inhibitor [54].

On the other hand, EC are homogenous, diploid and genetically stable [49], showing very rarely spontaneous mutations [73]. Therefore, therapeutic pharmacological strategies targeting EC will encounter less interference of the resistance processes described for other antitumors [49].

**Tumor angiogenesis as therapeutic target**

Research in the field of tumor angiogenesis follows three main directions: 1) identification of positive and negative regulators; 2) characterization of the mechanisms of action and the identification of either natural or synthetic inhibitors; and 3) quantification of the neo-vascularization in tumor biopsies as predictive tool for diagnosis [74].

Folkman et al. were the first to identify and isolate angiogenesis inhibitors. Their work encouraged other laboratories of the scientific-academic and pharmaceutical community throughout the world to develop angiogenesis inhibitors, some of them currently in use against cancer.

Starting from results of ongoing clinical trials (Table 1), the antiangiogenic therapy seems to be a promising strategy to treat cancer. They allow identifying several compounds showing antiangiogenic activity, with inhibitors of VEGF and its receptors as the most advanced candidates [75, 76]. Recently, the Bevacizumab (Avastin), a monoclonal antibody against the VEGF-A was approved by the FDA as the first systemic antiangiogenic [77].

Other inhibitors of angiogenesis under study are the shark cartilage [78] that recently failed in a phase III clinical trial; several flavonoids as genistein, derived from soybean that is able to inhibit MMP-2 expression in prostate cancer cells [79]. Additionally, there was demonstrated that apigenin, another natural flavonoid, show antiangiogenic effects involving the nitric oxide pathway [80]. Other recent studies have shown the epigallocatechin-3-gallate, the main flavonoid of green tea, able to suppress angiogenesis [81].

**Antiangiogenic therapy**

<table>
<thead>
<tr>
<th>Avascular phase</th>
<th>Vascular phase</th>
<th>Metastasic phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 2. The most convenient moment for antiangiogenic therapy. The tumor neovascularization process involves the release of pro-angiogenic factors by tumor cells (i.e., VEGF), causing endothelial activation (avascular), blood vessels growth (vascular phase) and subsequent tumor expansion (metastasic phase).</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Anti-angiogenic compounds in clinical development for cancer

<table>
<thead>
<tr>
<th>Registered drug (trademark) [company]</th>
<th>Action</th>
<th>Clinical trial</th>
<th>Type of cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab (Avastin™) [Genentech]</td>
<td>Inhibits VEGFA</td>
<td>Phase III combined with other chemotherapies</td>
<td>Metastatic colon-rectal cancer, lung non-small cell cancer, renal, ovary and metastatic breast cancer</td>
</tr>
<tr>
<td>SU11248 (Sutent™ [Pfizer])</td>
<td>Inhibits VEGFRs, PDGFR α, KIT and FLT3</td>
<td>Phase III monotherapy</td>
<td>Renal carcinoma</td>
</tr>
<tr>
<td>Bay 43-9006 (Nexavar™ [Bayer])</td>
<td>Inhibits VEGFRs, PDGFR, Raf</td>
<td>Phase III monotherapy</td>
<td>Renal carcinoma</td>
</tr>
<tr>
<td>AG-013736 (Axitinib [Pfizer])</td>
<td>Inhibits the tyrosine kinase portion of VEGFR and PDGFR-B</td>
<td>Phase III monotherapy</td>
<td>Metastatic renal carcinoma</td>
</tr>
<tr>
<td>PTK787/ZK22584 (vatalanib [Novartis])</td>
<td>Inhibits the tyrosine kinase portion of VEGFR1-3, PDGFR and KIT</td>
<td>Phase III</td>
<td>Renal and gastrointestinal carcinoma</td>
</tr>
<tr>
<td>VEGF-trap (Aflibercept™ [Sanofi-Aventis and Regeneron Pharmaceuticals, Inc])</td>
<td>VEGF A, VEGF B and PIGF</td>
<td>Phase III combined with other chemotherapies</td>
<td>Prostate, colon-rectal cancer, pancreatic cancer, gastric cancer and lung non-small cell cancer</td>
</tr>
</tbody>
</table>

mechanisms. This review pretended to overview the knowledge on angiogenesis and its role in cancer, also focused on the components of the signal transduction pathways involved in this process. The concept of cancer treatment in this century, considering the inhibition of angiogenesis, essential to tumor progression, represents an alternative to fight tumor resistance against therapeutic drugs. The antiangiogenic therapy is being available to surgery, chemo- and radio-therapy. The recent evaluation of antibodies, directed against VEGF as adjuvant therapy, has shown significant clinical benefits in cancer patients.

The introduction of several antiangiogenic agents or molecules in the arsenal against cancer has changed the natural history of this disease in humans. Now, the antiangiogenic drugs or medicines bring the opportunity to test not only a new class of antitumoral agent, but also a new and relevant mechanism of action. Given the success of most of the products produced by biotechnological means, the search for new products coming from natural sources constitute a significant challenge in Pharmacology up to date. Many of these and other discoveries would suggest strategies to improve the clinical benefits of the antiangiogenic therapy.


64. Griffioen AW. Cancer is angiogenesis dependent. Blood 2000;95(8):3023-34.


